OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Coombs on BTK Inhibitors and CAR T-Cell Therapy in CLL

July 14th 2023

Callie Coombs, MD, discusses treatment updates in patients with chronic lymphocytic leukemia.

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

July 14th 2023

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Dr Ged on Interim Data With Olaparib in DNA Repair Gene–Mutated mRCC

July 14th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the phase 2 ORCHID trial (NCT03786796).

Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma

July 14th 2023

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.

Dr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCC

July 14th 2023

David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).

Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor Use in HR+/HER2– Breast Cancer

July 14th 2023

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Dr. Tagawa on the Evolution of ADCs in mCRPC

July 14th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Dr Abushahin on Biomarker Testing in mCRC

July 13th 2023

Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.

Dr Danish on the Use of Novel Radiotherapy Approaches in Cancer Care

July 13th 2023

Adnan F. Danish, MD, discusses the use of novel radiotherapy approaches in cancer care.

Dr O’Brien on the Potential Role for Noncovalent BTK Inhibitors in MCL and CLL

July 13th 2023

Susan M. O’Brien, MD, discusses the potential role for noncovalent BTK inhibitors in the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

July 13th 2023

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast Cancer

July 13th 2023

Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.

Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma

July 13th 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

Dr Lowentritt on the Implications of Data on Real-World ASRI Efficacy in mCSPC

July 13th 2023

Benjamin H. Lowentritt, MD, FACS, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors in patients with mCSPC could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

July 12th 2023

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

July 12th 2023

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

Dr Levy on the Correlation Between Upfront NGS and OS Benefit in NSCLC

July 11th 2023

Benjamin Philip Levy, MD, discusses the relationship between upfront next-generation sequencing and survival outcomes in non–small cell lung cancer.

Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSL

July 11th 2023

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Dr Galsky on Atezolizumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

July 10th 2023

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer

July 10th 2023

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.